Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?

Author： Tankó László Karsdal Morten Christiansen Claus Leeming Diana

Publisher： Springer Publishing Company

ISSN： 0167-7659

Source： Cancer and Metastasis Reviews, Vol.25, Iss.4, 2006-12, pp. : 659-668

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BRCA1: What Do We Know? What Do We Think We Know? What Do We Really Need to Know?

By Buller R.E.

Gynecologic Oncology, Vol. 76, Iss. 3, 2000-03 ,pp. : 291-293

Elsevier

Access to resources Recommend Favorite

Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know

By Tassinari Davide

Supportive Care in Cancer, Vol. 16, Iss. 3, 2008-03 ,pp. : 311-312

Springer Publishing Company

Access to resources Recommend Favorite

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

By Lindsay Colin R Roxburgh Patricia Graham Janet

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 825-829

Future Medicine

Access to resources Recommend Favorite

Chemotherapy in alveolar soft part sarcomas - What do we know?

By Reichardt P. Lindner T. Pink D. Thuss-Patience P.C. Kretzschmar A. Dorken B.

European Journal of Cancer, Vol. 39, Iss. 11, 2003-07 ,pp. : 1511-1516

Elsevier

Access to resources Recommend Favorite

Duration of Chemotherapy for Early Stage Breast Cancer: Have We Reached the Limit? What is the Survival Impact of Amenorrhea?

By Hirsh Rebecca

Current Treatment Options in Oncology, Vol. 11, Iss. 3-4, 2010-12 ,pp. : 59-62

Springer Publishing Company

Access to resources Recommend Favorite